Related Experiment Video
Updated: Oct 3, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
An update on dapagliflozin for chronic kidney disease
1Department of Pharmacy Practice, Chapman University School of Pharmacy, Irvine, California, USA. mkelly@chapman.edu.
Abstract:
Dapagliflozin is an oral agent for type 2 diabetes mellitus (T2DM) belonging to the sodium/glucose cotransporter 2 inhibitor (SGLT2-I) class of antihyperglycemic medications. In clinical trials, dapagliflozin has also been shown to reduce cardiovascular and major renal events. In the DAPA-CKD trial, dapagliflozin significantly reduced the composite renal outcome in patients with chronic kidney disease (CKD). Dapagliflozin represents a new pharmacologic option for reducing CKD progression in patients with and without diabetes.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Dipeptidyl Peptidase 4 Inhibitors
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease IV: Nursing Management
Acute Kidney Injury V: Interprofessional Care

